About Avenu Medical
Avenu Medical is a Healthcare company based in Dana Point (United States) founded in 2010, and was acquired by Medtronic in September 2020. Image-guided catheter system is used for percutaneous AV fistula creation. Avenu Medical has raised $35.96 million across 5 funding rounds from investors including Medtronic. Avenu Medical offers products and services including Ellipsys Vascular Access System. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is Avenu Medical, Inc. Its competitors include Cardival Medical, Aziyo Biologics and EKOS Corporation; 3 of its 3 listed competitors have raised funding.
Company details
Avenu Medical was founded in 2010 in Dana Point, United States, focusing on the hemodialysis and vascular access sector. The Ellipsys Vascular Access System, an image-guided catheter, is employed to percutaneously form arteriovenous fistulas for hemodialysis patients. FDA approval has been granted for initiating a pivotal Phase III clinical trial under an IDE Exemption, supporting clinical evaluation in the US market.
- Headquarters Dana Point, United States
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website avenumedical.com
- Acquired by Medtronic (Sep 2020)
- Legal Name Avenu Medical, Inc.
Products & Services of Avenu Medical
Avenu Medical offers a comprehensive portfolio of products and services, including Ellipsys Vascular Access System.
Enables minimally invasive AV fistula creation for hemodialysis patients.
Funding Insights of Avenu Medical
Avenu Medical has successfully raised a total of $35.96M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $12 million completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35.96M
- Total Rounds 5
- Last Round Series C β $12M
- First Round $1M
(Sep 2010)
All 5 funding rounds of Avenu Medical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2018 | $12M | Series C | β | β | β |
| Feb 2017 | $13.11M | Series C | β | β | β |
| Dec 2015 | $6M | Series B | β | β | β |
| Jul 2013 | $3.86M | Series A | β | β | β |
| Sep 2010 | $1M | Seed | β | β | β |
1 investors in total: 1 institutional.
Investors in Avenu Medical
Avenu Medical has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Medtronic.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Medical equipment for treating over 30 chronic diseases is developed. | 1949 | medtronic.com | Minneapolis, United States |
Investor details for Avenu Medical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Avenu Medical
16 people are tracked at Avenu Medical (8 in leadership, 3 in board & advisors, 5 in team).
| Name | Role | Group |
|---|---|---|
Mark A. Ritchart | President & CEO | Leadership |
J. David Campbell | VP, Quality Assurance & Regulatory Affairs | Leadership |
Ed L. Chang | Chief Marketing Officer | Leadership |
Frank A. Hettmann | CFO | Leadership |
Gene B. Reu | EVP & General Manager | Leadership |
Dan Beney | VP, Sales | Leadership |
Brian Driscoll | VP, Marketing | Leadership |
Brad Kellerman | VP, Research & Development | Leadership |
T. Spencer Williamson | Director | Board & advisors |
Thomas W. McCandlish | Director | Board & advisors |
Steve H. Parker | Co-founder, Chairman & Director | Board & advisors |
Horacio Almazan | Operations Manager | Team |
Dk Kim | Sr. Quality Engineer | Team |
Julie Herweg Rvt | Clinical Application Specialist | Team |
Crystal Zerbe Lee | Clinical Application Specialist | Team |
Andrea Wampler | Clinical Application Specialist | Team |
Complete people profiles for Avenu Medical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Avenu Medical
4 dated milestones of Avenu Medical across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Avenu Medical is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series C, of $12.0M.
- Exit Acquired by Medtronic.
Competitors of Avenu Medical
Avenu Medical has 3 listed competitors in our database, 3 of them funded. They include Cardival Medical, Aziyo Biologics and EKOS Corporation.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cardivamedical.com | 2002 | Santa Clara, United States | $169.45M | 158 | A device for vascular access management is developed. | |
| aziyo.com | 2015 | Silver Spring, United States | $49.59M | 162 | Regenerative medicine products are developed for orthopedic and cardiovascular applications. | |
| ekoscorp.com | 1995 | Bothell, United States | $58.8M | Ultrasound thrombolytic devices for pulmonary embolism treatment are developed. |
Detailed competitors of Avenu Medical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Avenu Medical (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Avenu Medical
Complete news archive for Avenu Medical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avenu Medical
Avenu Medical was founded in 2010.
Avenu Medical is headquartered in Dana Point, United States. It is registered at Dana Point, California, United States.
Avenu Medical is a funded company, having raised a total of $35.96M across 5 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Sep 2010.
Avenu Medical was founded in 2010 in Dana Point, United States, focusing on the hemodialysis and vascular access sector. The Ellipsys Vascular Access System, an image-guided catheter, is employed to percutaneously form arteriovenous fistulas for hemodialysis patients. FDA approval has been granted for initiating a pivotal Phase III clinical trial under an IDE Exemption, supporting clinical evaluation in the US market.
Avenu Medical's top competitors include Cardival Medical, Aziyo Biologics and EKOS Corporation.
Avenu Medical offers Ellipsys Vascular Access System.
Avenu Medical has 1 investor. Key investors include Medtronic.
Avenu Medical operates through Avenu Medical, Inc..
Yes. Avenu Medical was acquired by Medtronic in September 2020.

